Carcinoma embryonic antigen (CEA), osteopontin (OPN), and Dickkopf-1 (DKK1) expressed in serum are associated with hypoxia in tumor progression. However, the role of these proteins in the plasma of patients with non-small cell lung cancer (NSCLC) is poorly understood. The diagnostic values of CEA combined with OPN or DKK1 were compared in non-small cell lung cancer. This study investigated the diagnostic value of CEA combined with OPN and DKK1, respectively, in NSCLC. Eighty patients with NSCLC (NSCLC group) and 60 patients with benign lung diseases (benign lung disease group) admitted to Shandong Provincial Third Hospital from May 2014 to January 2015 were selected as the study subjects. In addition, 60 healthy subjects undergoing normal physical examination were selected as healthy control group. The OPN and DKK1 in serum of the two groups were detected by enzyme linked immunosorbent assay (ELISA), and the CEA expression was measured by Electrochemical Photometric method. The diagnostic value of CEA combined with OPN and DKK1, respectively, in NSCLC was analyzed. The expression of CEA, OPN, and DKK1 in serum of NSCLC group was significantly higher than that of healthy control group and benign lung disease group (P<0.05). The expression of CEA, OPN and DKK1 in serum of NSCLC patients was correlated with tumor diameter, lymph node metastasis, degree of pathological differentiation and clinical stage (P<0.05). ROC curve for diagnosis of NSCLC was drawn by further combination of serum CEA and OPN. The AUC of combined diagnosis of CEA and OPN for NSCLC was 0.920 (95% CI, 0.875-0.964), and the diagnostic sensitivity and specificity were 87.50 and 86.67%, respectively; the AUC of combined diagnosis of CEA and DKK1 for NSCLC was 0.912 (95% CI, 0.866-0.958), and the diagnostic sensitivity and specificity were 92.50 and 76.67%, respectively. CEA, OPN and DKK1 may be involved in the occurrence and progression of NSCLC and have good sensitivity and specificity in the diagnosis of NSCLC and may be new biomarkers for the diagnosis of NSCLC.
IntroductionThe clinical symptoms of Chlamydia psittaci pneumonia are still poorly understood. This study was designed to summarize the clinical features and outcome of eight C. psittaci pneumonia patients diagnosed by targeted next generation sequencing (tNGS).MethodsWe included eight C. psittaci pneumonia patients admitted to our hospital from January 2021 to July 2022. The tNGS was performed to the samples collected from bronchoalveolar lavage fluid of each patient. Their clinical data were analysed, including baseline features, clinical symptoms, chest radiographic findings and laboratory examinations.ResultsThe tNGS sequence number for C. psittaci was in a range of 10 to 1722. The radiographic characteristics were mainly featured by patchy consolidation shadows, ground‐glass density shadows, air bronchogram and slight pleural effusion. Within 1–3 days after hospitalization, most patients showed increased neutrophil ratio, C‐reactive protein and erythrocyte sedimentation rate, and decreased lymphocyte count, total protein, albumin and prealbumin. Some patients showed increased glutamic‐pyruvic transaminase, glutamic‐oxaloacetic transaminase and lactate dehydrogenase levels. Three critically ill patients showed increased creatine kinase, creatine kinase isoenzyme and high‐sensitivity troponin T (hs‐TnT) levels.ConclusionsA poultry or bird contact history, typical flu‐like symptoms, patchy consolidation, ground‐glass density shadow and air bronchogram may contribute to the diagnosis and treatment of C. psittaci pneumonia. Increase in creatine kinase, creatine kinase isoenzyme and hs‐TnT may indicate a severe condition. Moxifloxacin and minocycline were effective in the management of C. psittaci pneumonia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.